Tryptamine Therapeutics Limited, previously Exopharm, engages in the development and commercialization of exosomes as therapeutic agents. The company is headquartered in Melbourne, Victoria. The firm’s principal activities include pipeline products analysis and selection, technology development and validation, and commercial collaborations. The firm operates through the regenerative medicine and biopharmaceutical drug development segment. Its exosome technologies solve the needs for the success of exosome medicines. Its technologies include LEAP manufacturing technology, LOAD active pharmaceutical ingredients (APIs) loading technologies, and EVPS tropism technologies. The firm is developing Engineered EVs (EEVs), an emerging form of precision medicine with application in areas, such as neurology, cardiology, and oncology. Its EEV technology includes EVPS to provide tissue tropism to exosomes and LOAD to load in APIs, such as messenger ribonucleic acid (mRNA).
Tryptamine Therapeutics Limited (ASX: TYP)
- Home
- Tryptamine Therapeutics Limited (ASX: TYP)
Here are the latest articles on Tryptamine Therapeutics Limited (ASX: TYP)
Tryptamine Therapeutics’ psilocybin trials deliver pain relief to all patients
August 13, 2024
With their new name to reflect the journey their patients undergo when treated with psychedelic drugs, Tryptamine Therapeutics (ASX: TYP) has confirmed that all patients suffering from fibromyalgia that took their TRP-8802 drug, an oral psilocybin formulation, demonstrated significant pain relief. The study, conducted in collaboration with the University of Michigan (UOM), was presented at
Magic mushrooms company Tryp prepares for ASX listing via $14.3m backdoor merger with Exopharm
March 11, 2024
Canadian biotech company Tryp Therapeutics (CSE: TRYP) is set to list on the ASX through a backdoor merger with genetic medicines developer Exopharm (ASX: EX1) in a $14.3 million acquisition agreement. Following this agreement, Exopharm will change its name to Tryp and re-list on the ASX. On completion of the Transaction (Completion), Exopharm will be
The age of mRNA therapeutics is now – with exosomes
November 24, 2022
mRNA therapeutics are now expected to become the third major class of drugs. But converting their promise into reality, just like what happened with electric vehicles, is not without technical challenges. In the case of electric vehicles, their sales only really took off once the complex new battery technologies which enabled high-performance together with extended
Special delivery: unique drug delivery system receives new US patent
December 22, 2021
Let’s rewind to Year 10 biology- you know that mitochondria is the powerhouse of the cell, chances are you vaguely remember the golgi apparatus but do you remember what an exosome is? Exosomes, or extracellular vesicles are little packages delivering molecules and enhancing cell-to-cell communication. Clinical- stage biopharmaceutical company Exopharm (ASX: EX1) is utilising exosomes
Recent Articles
